11
Jul
2019
Better Cancer Treatment Through Better Information: Cindy Perettie on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Jul
2019
BioNTech Snags $320m, Roche/Spark Delay, & Summer Job Switches
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Jul
2019
Cancer Survivor and Cancer Drug Developer: Laura Shawver on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Jul
2019
Has the Time Come for a US NICE?
There is growing discontent among many healthcare stakeholders with the Institute for Clinical and Evidence Review known as ICER, something which may not surprise many TR readers. Recently, I had the opportunity to moderate a panel on value-based agreements for the CBI/EBD Group Rare Disease Innovation & Partnering Summit in Boston. Among the topics that the panel discussed was the... Read More
27
Jun
2019
AbbVie & Allergan (Groan), Adaptive Headlines IPO Rush, & FDA Cops on the Beat
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jun
2019
Just Because You Can Doesn’t Mean You Should: Gene Therapy is Not the Solution to Every Problem
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Jun
2019
Pfizer’s Wager on Small Molecules, Summer IPO Flurries, Gilead’s Protein Degrader Play
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jun
2019
Who Will Be the Next Celgene of Dealmaking?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jun
2019
Predicting Who Will Benefit from Cancer Drugs: Liz O’Day on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
May
2019
Organs-on-a-chip, Organoids Start to Deliver Results as an Alternative Preclinical Route
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
May
2019
Third Rock and Friends Bet $110M On Thrive, a Hopkins-Inspired Cancer Screening Startup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
May
2019
Baseball Comes to Surprise Medical Billing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
May
2019
From Open Biology to Pharma Leadership: Jay Bradner of Novartis on The Long Run
Today’s guest on The Long Run is Jay Bradner. Jay is the president of the Novartis Institutes for Biomedical Research (NIBR). This is one of the heavyweight organizations in Big Pharma industry R&D. When Novartis planted this operation in the heart of Cambridge, Mass. more than a decade ago, it was the start of a trend toward Big Pharma R&D... Read More
20
May
2019
Pain Drug Development Flounders in the Opioid Crisis, but Novel Mechanisms Emerging
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
May
2019
Amgen Swings for the RAS Fence, Gilead’s Grilling on Price, & Agios Enlarges the Pie
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
May
2019
LivLyme and the Many Hats of Patient Advocacy Organizations
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
May
2019
An Elephant for Immunology Drugs: Sheila Gujrathi on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
May
2019
Thank You, Biotech: Kili Climb to Fight Has Crushed Its $1m Goal for Cancer Research
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
May
2019
Investing from the Heart to Find New ALS Therapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Apr
2019
Membraneless Organelles Offer New Drug Discovery Opportunities
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.